Health Screenings Library

Free home FIT kit every 2 years via the National Bowel Cancer Screening Program (NBCSP). Ages 45–49 can opt-in to request a free kit.

BreastScreen Australia actively invites ages 50–74 for free 2-yearly mammograms. Ages 40–49 and 75+ may attend on request—discuss benefits/harms with a clinician.

Primary HPV test every 5 years; clinician-collected or self-collection option available.

Not a population screening program. PSA testing should follow shared decision-making after discussing benefits/harms.

Use AUSDRISK to assess risk; perform blood testing if high risk. Earlier and/or more frequent checks for some ethnicities and First Nations peoples.

Opportunistic or scheduled BP measurement from adulthood; check more often if elevated or at higher cardiovascular risk. Confirm raised readings with repeat/ambulatory or home monitoring.

GP check using Australian CVD risk calculator; includes BP, lipids and risk discussion.

Screen at 65+; earlier testing if risk factors (e.g., prior fragility fracture, long-term steroids, early menopause).

Consider earlier testing if risk factors (e.g., hypogonadism, prolonged steroids, prior fracture).

One-time ultrasound for men 65–75 who have ever smoked; selective consideration for never-smokers based on risk (no routine screening for women without risk).

2-dose Shingrix® course funded under NIP for people aged 65+; additional funded eligibility for First Nations people 50+ and some immunocompromised ≥18.

Annual vaccination recommended; funded for groups at higher risk (e.g., ≥65, First Nations, pregnancy, certain medical conditions).

Adult pneumococcal vaccination per Australian Immunisation Handbook; funded for non-Indigenous adults ≥70 and First Nations adults ≥50 (plus risk-based indications).

National Lung Cancer Screening Program (NLCSP): annual LDCT for eligible high-risk adults. Eligibility includes age, pack-years and current/recent smoking. Discuss benefits/harms.

For people with moderate/high familial risk or known hereditary syndromes. Interval depends on specific risk category and prior findings.

Annual test for sexually active people <30. Include urine/vaginal (and throat/rectal swabs if indicated).

Minimum annual testing; some groups (e.g., MSM) may benefit from 3-monthly checks. Include HIV Ag/Ab and syphilis serology; add chlamydia/gonorrhoea as indicated.

One-off triple serology (with repeat if ongoing risk). Vaccinate if non-immune; link care if positive.

Antibody test with reflex RNA if positive; re-test if ongoing risk. Curative treatment available.

Targeted CKD case-finding with serum creatinine/eGFR, urine ACR, and BP in at-risk groups.

Comprehensive dilated eye exam or retinal photography for people with diabetes (often annual; up to 2-yearly if low risk per clinician advice).

Universal screening with OGTT at 24–28 weeks’ gestation; consider earlier testing if high risk (e.g., prior GDM, BMI, family history, some ethnicities).

[Optional] Australia has no population skin-check program; risk-based GP/dermatology checks plus regular self-exams are advised. Seek review for any new or changing lesions.

[Optional] Routine comprehensive eye exam every ~2 years from 50; earlier/more frequent if risk (e.g., glaucoma family history).

[Optional] Regular dental exams help prevent tooth decay and gum disease; many people benefit from 6–12-monthly visits.

[Optional] Targeted testing of people at increased risk of latent TB infection or progression; choose TST/IGRA per local guideline and BCG history.

For people at high risk (e.g., chronic HBV, cirrhosis from any cause). Specific age thresholds vary by risk; discuss surveillance plan with clinician.

Population screening beyond 74 is not recommended; discuss benefits/harms and prior results with your GP if considering continued FIT/colonoscopy.

Opportunistic screening in primary care (pulse palpation or brief ECG) for ≥65; follow with ECG if irregular pulse.

Have hearing checked from ≥65; sooner/more often if symptoms or risk (noise exposure, ototoxic meds).

Book first antenatal visit by 10 weeks. Typical early tests: blood group & antibody screen, full blood count, HIV/HBV/HCV/syphilis, rubella/varicella immunity, urine culture; consider first-trimester ultrasound for dating and multiple pregnancy.

Immunocompetent 9–25 years: 1-dose schedule; ≥26 or immunocompromised: 3-dose schedule (clinical advice/funding differs).

Give one dose of dTpa in each pregnancy, preferably 20–32 weeks’ gestation; funded under NIP.

Adults should receive a tetanus-containing booster at 50 and 65 years if >10 years since last dose; consider decennial boosters in some circumstances.

Follow current ATAGI advice on timing by age and risk (older and immunocompromised may need more frequent boosters).

Comprehensive annual foot assessment; more frequent if at high risk or with prior ulcer/neuropathy.

Population screening is not recommended; perform regular self-checks and seek GP/dermatology review. High-risk individuals may need periodic clinician skin exams.

Single dose of maternal RSV vaccine (Abrysvo®) recommended from 28–36 weeks' gestation; aligns with current Immunisation Handbook advice.

If a clinic or home reading is high, confirm with repeat measurements, 24-hour ambulatory BP monitoring (ABPM) or structured home BP monitoring (HBPM) before treatment decisions.

If BP is elevated, organise a timely follow-up (weeks–months, not years) to review confirmation readings and management with your clinician.